ARTICLE | Clinical News
Orbactiv oritavancin regulatory update
April 13, 2015 7:00 AM UTC
The European Commission approved IV Orbactiv oritavancin from The Medicines Co. to treat acute bacterial skin and skin structure infections (ABSSSIs) caused by Gram-positive bacteria, including methic...